{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:36:04Z","timestamp":1785036964541,"version":"3.55.0"},"reference-count":26,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"\n Background & objectives:<\/jats:title>\n Patients with autoimmune rheumatic diseases may be at an increased risk of infection due to disease and use of disease-modifying antirheumatic drug (DMARD) therapy. The present study was done to evaluate the immune response to influenza vaccination in patients with rheumatoid arthritis (RA).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Fifty one RA patients on stable methotrexate (MTX) therapy (\u226515 mg\/wk), 51 newly diagnosed DMARD-na\u00efve RA patients and 45 healthy controls received a single dose of inactivated seasonal trivalent influenza vaccine. Blood samples were collected just prior to and four weeks after vaccination. Pre- and post-vaccination antibody titres against the three virus strains were measured by hemagglutination inhibition assay. The impact of age, gender, DMARD treatment and pre-vaccination seroprotection on response to the vaccine was assessed by binary logistic regression analysis for each of the virus strains.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Pre-vaccination antibody titres were found to be high in the three study groups for all influenza strains, except for Yamagata strain, the titres for which were low in healthy controls. Trivalent influenza vaccination was found to be safe and stimulated a good antibody response in all study groups. On regression analysis, there was no association of age, gender or MTX therapy with vaccine response, except for Yamagata strain where healthy controls had higher positive immune response (P=0.008; odds ratio \u2013 3.37, 95% confidence interval: 1.36-8.32).<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n Our results indicated that influenza vaccination was safe in RA patients with no detrimental effect on disease activity. MTX therapy at a dose \u226515 mg\/wk did not affect the vaccine response. Presence of high pre-vaccination seroprotective antibody levels in the study population indicates the need for re-examination of recommended annual influenza vaccination in such subgroups of population.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_920_15","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:03:38Z","timestamp":1734635018000},"page":"464-470","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis"],"prefix":"10.25259","volume":"145","author":[{"given":"Vikramraj K.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandhini","family":"Bhashini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Karthik","family":"Balajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Sistla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash Chandra","family":"Parija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vir Singh","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-7-20241212","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R2-7-20241212","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun Rev"},{"key":"R3-7-20241212","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.injr.2015.04.002","article-title":"Disease burden of rheumatic diseases in India: COPCORD perspective","volume":"10","author":"Chopra","year":"2015","journal-title":"Indian J Rheumatol"},{"key":"R4-7-20241212","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R5-7-20241212","first-page":"149","article-title":"Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis","volume":"13","author":"Myllykangas-Luosuj\u00e4rvi","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"R6-7-20241212","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/ard.49.6.363","article-title":"Mortality and survival in rheumatoid arthritis: A 25 year prospective study of 100 patients","volume":"49","author":"Reilly","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"R8-7-20241212","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R9-7-20241212","first-page":"534","article-title":"Emergence of pandemic 2009 influenza A H1N1, India","volume":"135","author":"Choudhry","year":"2012","journal-title":"Indian J Med Res"},{"key":"R12-7-20241212","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R13-7-20241212","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology (Oxford"},{"key":"R14-7-20241212","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor a, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R15-7-20241212","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2011.11.109","article-title":"Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review","volume":"30","author":"Agarwal","year":"2012","journal-title":"Vaccine"},{"key":"R16-7-20241212","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrrheum.2009.196","article-title":"Vaccines and autoimmunity","volume":"5","author":"Agmon-Levin","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"R17-7-20241212","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/art.30325","article-title":"Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study","volume":"63","author":"Gabay","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R20-7-20241212","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of A\/H1N1 vaccination in immune-mediated disease \u2013 A prospectively controlled vaccination study","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology (Oxford"},{"key":"R21-7-20241212","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R22-7-20241212","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/rheumatology\/41.12.1457","article-title":"Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis","volume":"41","author":"Kumar","year":"2002","journal-title":"Rheumatology (Oxford"},{"key":"R24-7-20241212","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R25-7-20241212","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R26-7-20241212","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology (Oxford"},{"key":"R27-7-20241212","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford"},{"key":"R28-7-20241212","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3201\/eid1605.091678","article-title":"Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore","volume":"16","author":"Tang","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"R29-7-20241212","first-page":"351","article-title":"A survey of levels of antibodies against influenza viruses in the population of Wuxi City","volume":"25","author":"You","year":"2011","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"R30-7-20241212","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2334-10-255","article-title":"Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India","volume":"10","author":"Tandale","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R31-7-20241212","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0140-6736(09)62126-7","article-title":"Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study","volume":"375","author":"Miller","year":"2010","journal-title":"Lancet"},{"key":"R32-7-20241212","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.2807\/ese.17.02.20052-en","article-title":"Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany","volume":"17","author":"Cramer","year":"2012","journal-title":"Euro Surveill"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201745040-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:58:43Z","timestamp":1751497123000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/effect-of-disease-modifying-antirheumatic-drug-therapy-on-immune-response-to-trivalent-influenza-vaccine-in-rheumatoid-arthritis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_920_15","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}